Artikel Jurnal
The relationship between myasthenia gravis and COVID-19: a systematic review
Introduction: Viral infection such as coronavirus disease 2019 (COVID-19) can exacerbate and aggravate neurological disorders due to autoimmune etiology like myasthenia gravis (MG). Experimental therapies used in COVID-19 are
also factors that can cause the worsening of MG symptoms. This review aimed to assess and conclude the researchbased study systematically to analyze the relationship of MG and COVID-19.
Method: This study was conducted in accordance to Cochrane handbook for systematic reviews and the guideline
of preferred reporting items for systematic review and meta-analysis (PRISMA) and synthesis without meta-analysis
(SWiM) in systematic reviews: reporting guideline. Inclusion criteria in this review were primary studies of every
design, articles published in English around January 2000–October 2021, and the study used human as subject. A
systematic literature fnding was applied in 15 electronic scientifc resources. The authors evaluated the study quality
and risk of bias of each retrieved article.
Results: The authors found the study through electronic scientifc resources that met inclusion and exclusion criteria.
The authors evaluated 362 articles identifed in literature searching, 22 articles met the criteria for this review and then
underwent the evaluation of study quality and risk of bias.
Conclusion: COVID-19 infection can increase the risk of new-onset MG, myasthenic crisis, respiratory failure, and
mortality rate due to cytokine storm in MG patients. The management of COVID-19 patients with MG is tailored to
each person and based on national guidelines and local expert recommendations.
Keywords: Autoimmune, COVID-19, Myasthenia gravis, Neurology
No other version available